Petrus J de Vries Selected Research

Angiomyolipoma

1/2020	Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas.
1/2019	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry.
1/2019	Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness.
1/2017	TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients.
1/2017	Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
1/2016	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
1/2016	Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
7/2015	Neurological and neuropsychiatric aspects of tuberous sclerosis complex.
3/2013	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
6/2011	Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Petrus J de Vries Research Topics

Disease

53	Tuberous Sclerosis (Bourneville's Disease) 10/2023 - 02/2007
17	Inborn Genetic Diseases (Disease, Hereditary) 01/2023 - 02/2007
13	Seizures (Absence Seizure) 12/2021 - 08/2007
10	Angiomyolipoma 01/2020 - 06/2011
9	Epilepsy (Aura) 01/2023 - 05/2011
8	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 01/2013
7	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 01/2019 - 01/2008
3	Neoplasms (Cancer) 01/2023 - 01/2016
3	Autism Spectrum Disorder 01/2021 - 01/2014
2	Intellectual Disability (Idiocy) 01/2023 - 02/2007
2	Rare Diseases (Rare Disease) 01/2021 - 11/2014
2	Infantile Spasms (West Syndrome) 01/2021 - 03/2019
2	Hemorrhage 01/2017 - 01/2016
2	Stomatitis 03/2013 - 01/2013
2	Neurofibromatosis 1 (Neurofibromatosis Type I) 05/2011 - 07/2010
1	Neurologic Manifestations (Neurological Manifestations) 01/2021
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Autistic Disorder (Autism) 08/2017
1	Angiofibroma 01/2017
1	Rhabdomyoma 01/2017
1	Flank Pain 01/2017
1	Hydrocephalus (Hydrocephaly) 01/2016
1	Nasopharyngitis 03/2013
1	Acne Vulgaris 03/2013
1	Disease Progression 03/2013
1	Fever (Fevers) 01/2013
1	LEOPARD Syndrome (Syndrome, LEOPARD) 05/2011
1	Status Epilepticus (Complex Partial Status Epilepticus) 05/2011
1	Tuberous Sclerosis 1 06/2010

Drug/Important Bio-Agent (IBA)

44	trans-sodium crocetinate (crocetin)IBA 10/2023 - 02/2007
14	Everolimus FDA Link 12/2021 - 01/2013
9	TOR Serine-Threonine KinasesIBA 01/2021 - 05/2011
5	MTOR InhibitorsIBA 03/2019 - 07/2015
5	Proteins (Proteins, Gene)FDA Link 12/2015 - 08/2007
4	Sirolimus (Rapamycin)FDA Link 03/2013 - 01/2008
3	lipoarabinomannan (LAM)IBA 01/2019 - 06/2011
2	Anticonvulsants (Antiepileptic Drugs)IBA 01/2018 - 10/2016
2	Tuberous Sclerosis Complex 2 ProteinIBA 06/2010 - 08/2007
1	Vigabatrin FDA Link 01/2021
1	SteroidsIBA 01/2021
1	gamma-Aminobutyric Acid (GABA)IBA 03/2019
1	Aminobutyrates (Aminobutyric Acid)IBA 03/2019
1	adriamycin-14-valerate (AD 48)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	Mechanistic Target of Rapamycin Complex 1IBA 06/2011
1	Kainic Acid (Kainate)IBA 05/2011
1	TensinsIBA 07/2010
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 07/2010
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2010
1	Tuberous Sclerosis Complex 1 ProteinIBA 08/2007

Therapy/Procedure

7	Therapeutics 12/2021 - 01/2008
1	Nephrectomy 01/2017